PL3024485T3 - Zastosowanie partnera wiążącego cd6 i oparty na tym sposób - Google Patents

Zastosowanie partnera wiążącego cd6 i oparty na tym sposób

Info

Publication number
PL3024485T3
PL3024485T3 PL14828881T PL14828881T PL3024485T3 PL 3024485 T3 PL3024485 T3 PL 3024485T3 PL 14828881 T PL14828881 T PL 14828881T PL 14828881 T PL14828881 T PL 14828881T PL 3024485 T3 PL3024485 T3 PL 3024485T3
Authority
PL
Poland
Prior art keywords
application
binding partner
partner
binding
Prior art date
Application number
PL14828881T
Other languages
English (en)
Inventor
Pradip Nair
Ramakrishnan Melarkode
Bala S. Manian
Abhijit Barve
Usha BUGHANI
Jose Enrique Montero Casimiro
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of PL3024485T3 publication Critical patent/PL3024485T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
PL14828881T 2013-07-23 2014-07-23 Zastosowanie partnera wiążącego cd6 i oparty na tym sposób PL3024485T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3264CH2013 2013-07-23
EP14828881.4A EP3024485B1 (en) 2013-07-23 2014-07-23 Use of a cd6 binding partner and method based thereon
PCT/IB2014/063345 WO2015011658A1 (en) 2013-07-23 2014-07-23 Use of a cd6 binding partner and method based thereon

Publications (1)

Publication Number Publication Date
PL3024485T3 true PL3024485T3 (pl) 2021-06-14

Family

ID=52392806

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14828881T PL3024485T3 (pl) 2013-07-23 2014-07-23 Zastosowanie partnera wiążącego cd6 i oparty na tym sposób

Country Status (15)

Country Link
US (3) US10189899B2 (pl)
EP (3) EP3024485B1 (pl)
JP (4) JP6530391B2 (pl)
KR (3) KR102405247B1 (pl)
AR (1) AR097038A1 (pl)
AU (3) AU2014294616B2 (pl)
CA (1) CA2920368C (pl)
DK (1) DK3024485T3 (pl)
ES (1) ES2843683T3 (pl)
HK (1) HK1225298A1 (pl)
NZ (1) NZ746944A (pl)
PL (1) PL3024485T3 (pl)
PT (1) PT3024485T (pl)
TW (1) TW201511772A (pl)
WO (1) WO2015011658A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Cd6のリン酸化を低減させるためのイトリズマブの使用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US20230364233A1 (en) * 2020-09-28 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd6 modification
JP2023552762A (ja) * 2020-12-04 2023-12-19 エクイリウム,インコーポレイテッド Cd6high細胞を選択的に標的化してteff細胞の活性を低下する方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
WO1995012614A1 (en) 1993-11-02 1995-05-11 Duke University Cd6 ligand
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
KR20000064710A (ko) 1996-03-20 2000-11-06 제넨테크, 인코포레이티드 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물
WO1998043089A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
WO2001070984A2 (en) 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
HK1054316A1 (zh) 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
CA2654794A1 (en) 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 B-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
KR101482956B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 류마티스 관절염의 진단 및 치료에 사용되는 항-cd6 단일클론성 항체를 포함하는 약학 조성물
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
JP2010111581A (ja) * 2007-01-25 2010-05-20 Imuno:Kk ドーパミンd2様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
NZ579251A (en) * 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
WO2009092087A2 (en) * 2008-01-18 2009-07-23 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human th17 cells
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
EP2501408B1 (en) 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
JP7065085B2 (ja) 2016-10-18 2022-05-11 バイオコン・リミテッド Cd6のリン酸化を低減させるためのイトリズマブの使用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN112424226B (zh) 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体

Also Published As

Publication number Publication date
KR20190120426A (ko) 2019-10-23
KR20160033786A (ko) 2016-03-28
WO2015011658A1 (en) 2015-01-29
JP2022145689A (ja) 2022-10-04
CA2920368A1 (en) 2015-01-29
JP7221264B2 (ja) 2023-02-13
DK3024485T3 (da) 2020-12-07
KR20210088739A (ko) 2021-07-14
AU2021240292B2 (en) 2025-01-23
KR102405247B1 (ko) 2022-06-07
KR102276745B1 (ko) 2021-07-14
JP6530391B2 (ja) 2019-06-12
NZ716381A (en) 2021-06-25
JP2021038266A (ja) 2021-03-11
JP2016525538A (ja) 2016-08-25
EP3024485A1 (en) 2016-06-01
JP2019112446A (ja) 2019-07-11
EP3024485B1 (en) 2020-11-18
AU2014294616B2 (en) 2019-07-11
TW201511772A (zh) 2015-04-01
PT3024485T (pt) 2021-01-25
US20190345247A1 (en) 2019-11-14
AU2019246781B2 (en) 2021-07-01
US10189899B2 (en) 2019-01-29
JP6868655B2 (ja) 2021-05-12
AU2014294616A1 (en) 2016-02-18
HK1225298A1 (zh) 2017-09-08
EP3738613A1 (en) 2020-11-18
CA2920368C (en) 2023-03-21
ES2843683T3 (es) 2021-07-20
AR097038A1 (es) 2016-02-17
NZ746944A (en) 2021-07-30
US20220025038A1 (en) 2022-01-27
KR102034757B1 (ko) 2019-10-21
AU2021240292A1 (en) 2021-10-28
US11028168B2 (en) 2021-06-08
US20160152705A1 (en) 2016-06-02
EP3936148A1 (en) 2022-01-12
AU2019246781A1 (en) 2019-10-31
EP3024485A4 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
PT3052485T (pt) Compostos heterocíclicos e suas utilizações
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK2968173T3 (da) Heterocykliske forbindelser og anvendelser deraf
EP2962216A4 (en) COMMON USE OF APPLICATION STATES
EP3039131C0 (en) ENZYME COMPOSITION AND USES
EP2987933A4 (en) HINGE
LT3038654T (lt) Naujas panaudojimas
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
PL3024485T3 (pl) Zastosowanie partnera wiążącego cd6 i oparty na tym sposób
BR302013005487S1 (pt) Configuração aplicada em aumotóvel
DK2978414T3 (da) Sammensætning omfattende hydrocortison
BR302013005994S1 (pt) Configuração aplicada em mixer
FR3007291B1 (fr) Composition cicatrisante et utlisation
EP2985312A4 (en) AGGREGATE AND COMPOSITION
BR302013002605S1 (pt) Configuração aplicada em banqueta
BR302013005488S1 (pt) Configuração aplicada em relógio
BR302013005118S1 (pt) Configuração aplicada em relógio
BR302013005120S1 (pt) Configuração aplicada em relógio
BR302013005122S1 (pt) Configuração aplicada em relógio
BR302013005123S1 (pt) Configuração aplicada em relógio
BR302013005119S1 (pt) Configuração aplicada em relógio
BR302013005124S1 (pt) Configuração aplicada em relógio